Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab versus standard glucocorticoid-based care for immune checkpoint inhibitor-induced inflammatory arthritis
ISRCTN18217497Phase 2Recruiting
- Sponsor
- University of Birmingham
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial in immune checkpoint inhibitor-associated arthritis (ICI-IA) comparing Standard of care with Adalimumab without glucocorticoids (2 arms). Primary endpoint: Glucocorticoid-free arthritis remission rate at 24 weeks. Started Apr 2025; status: recruiting.
02
Drugs
adalimumabprednisolone
03
Conditions
immune checkpoint inhibitor-associated arthritis (ICI-IA)
Beyond the preview
Go deeper on ISRCTN18217497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18217497.